In support of MetalloBio’s commercialisation strategy, the company has recently secured patents in: Australia, Brazil, India, Japan, Mexico, the USA, and is awaiting validation in a number of countries covered by the European Patent Convention (EPO). Patents are pending in several other territories. This is validation that the core inventions meet stringent conditions of novelty and applicability. MetalloBio is working on entirely novel, first-in-class compounds, completely different in their chemistry and action from existing antibiotics. The sustained efforts of our team have supported this recent slew of granted patents, expanding our intellectual property portfolio which underpins the company’s R&D  programmes and business strategy. Securing patents in such key markets adds to the value of our research, and bolsters our position in the antimicrobial drug development sector. 

‍